TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31113362
Drug: Stratified therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified therapy based on mechanistic drivers and biomarkers of AF
Study: 24438500
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (2 mSv)
Study: 24438500
Drug: Standard-dose computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose computed tomography (8 mSv)
Study: 17303766
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing (4 individual, weekly sessions)
Study: 15675575
Drug: EGF receptor
Normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF receptor tyrosine kinase inhibitors (gefitinib and erlotinib)
Study: 10422996
Drug: Pharmacist recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist recommendations related to drug ordering
Study: 1950033
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg
Study: 7399797
Drug: Topical extract
Normalized name: GLYCERIN 13.226 g in 100 mL TOPICAL EXTRACT [WELLAGE 4D Gold Essence]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical extract of Peganum harmala
Study: 23415311
Drug: Lurasidone 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 160 mg
Study: 24385309
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 600 mg
Study: 11754119
Drug: Nimesulide drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide drop formulation (50 mg x ml(‐1), Medley S/A Indústria Farmacêutica, Brazil)
Study: 11754119
Drug: Standard nimesulide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nimesulide drop formulation (Nisulid, 50 mg x ml(‐1), Astra Médica, Brazil)
Study: 8033369
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (n = 38)
Study: 792665
Drug: Encephabol (pyritinol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encephabol (pyritinol, pyrithioxine) administered orally, parenterally, and combined
Study: 20952100
Drug: Antithrombin treatment
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombin treatment (unfractionated heparin, low-molecular-weight heparin, or bivalirudin)
Study: 10671927
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antihypertensive medication
Study: 8140382
Drug: Topical vasoconstrictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vasoconstrictor pre-treatment
Study: 8140382
Drug: No vasoconstrictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vasoconstrictor pre-treatment (control)
Study: 4030197
Drug: PPA 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPA 37.5 mg (therapeutic dose)
Study: 25073857
Drug: Insulin Sensitization
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Sensitization (IS)
Study: 25073857
Drug: Insulin Provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Provision (IP)
Study: 20373130
Drug: Early abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early abciximab administration before transfer to cathlab (group EA)
Study: 20373130
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab administration during PPCI (group LA)
Study: 20373130
Drug: Selective abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective abciximab administration during PPCI (group SA)
Study: 18508946
Drug: Tonsillectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonsillectomy plus steroid pulse therapy (group C)
Study: 18508946
Drug: Steroid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid pulse monotherapy (group M)
Study: 31841078
Drug: Lumbar Stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar Stabilization Treatment (LST)
Study: 31841078
Drug: Cognitive Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Functional Treatment (CFT)
Study: 28317885
Drug: Magnesium-aluminium antacid
Normalized name: Magnesium aluminium silicate
DrugBank: Magnesium Aluminum Silicate (DB11230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium-aluminium antacid gel
Study: 24791346
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% lotion applied twice with a one week interval
Study: 24791346
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral ivermectin
Study: 24791346
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ivermectin
Study: 16449486
Drug: Nalmefene 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 25 mg/day
Study: 16449486
Drug: Nalmefene 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 50 mg/day
Study: 16449486
Drug: Nalmefene 100
Normalized name: nalmefene 100 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalmefene 100 mg/day
Study: 15290730
Drug: LEF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEF (10 mg/day, no loading dose) + MTX
Study: 15290730
Drug: PLA +
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PLA + MTX switched to LEF (10 mg/day, no loading dose)
Study: 15290730
Drug: LEF (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEF (no loading dose)
Study: 11273907
Drug: Insulin-enhanced cardioplegia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-enhanced cardioplegia (Humulin R 10 IU/L, Insulin group, n = 243)
Study: 11273907
Drug: Insulin-enhanced cardioplegia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-enhanced cardioplegia
Study: 11049005
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac (75 mg)
Study: 31433134
Drug: EndoUltra: 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoUltra: 2.5 ml of 7% MA for 30 s, followed by EndoUltra activation for 30 s
Study: 31433134
Drug: EndoSafe: EndoSafe
Approvals — FDA: no, EMA: no, PMDA: no
Description: EndoSafe: EndoSafe irrigation system for 1 minute using 5 ml of 7% MA
Study: 31433134
Drug: Side‐vented needle:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Side‐vented needle: 30 gauge needle irrigation for 1 min using 5 ml of 7% MA
Study: 25450818
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg/day, n=46)
Study: 25450818
Drug: Metformin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1000 mg/day, n=42)
Study: 25450818
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of Pioglitazone and Metformin
Study: 18281113
Drug: Magnesium orotate
Normalized name: Magnesium orotate
DrugBank: Magnesium orotate (DB13786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium orotate (6000 mg for 1 month, 3000 mg for about 11 months, n=40)
Study: 16948809
Drug: RWJ-351647 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-351647 (1, 2, and 5 mg doses)
Study: 16948809
Drug: RWJ-351647 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-351647 (5 mg)
Study: 11380515
Drug: NG-Monomethyl-L-arginine (L-NMMA)
Normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG-Monomethyl-L-arginine (L-NMMA)
Study: 24929883
Drug: Halobetasol 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol 0.05% ointment
Study: 18566839
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide therapy
Study: 18566839
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous dexamethasone and oral cyclophosphamide therapy
Study: 16783294
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing Lactobacillus acidofilus
Study: 16783294
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing Lactobacillus acidofilus + oral Lactobacillus paracasei subsp paracasei F19
Study: 14557449
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose soy isoflavones (1.0 g soy extracts, approximately 80 mg isoflavones)
Study: 14557449
Drug: Mid-dose soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose soy isoflavones (0.5 g starch, 0.5 g soy extracts, approximately 40 mg isoflavones)
Study: 14557449
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g starch)
Study: 8871338
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no self-hypnotic relaxation)
Study: 25920599
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (placebo)
Study: 6338794
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid therapy (combined results)
Study: 27009620
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker (n=833)
Study: 27009620
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (n=821)
Study: 27009620
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockade (n=830)
Study: 27009620
Drug: Evening variability
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening variability independent of the mean (before treatment)
Study: 27009620
Drug: Home BPV
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home BPV captured after monotherapy
Study: 20142543
Drug: Angiotensin-receptor blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-receptor blocker (losartan potassium) or angiotensin-converting enzyme inhibitor (enalapril maleate)
Study: 17324145
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg once daily for 12 weeks, followed by placebo for 2 weeks and then metoprolol succinate 95 mg once daily for 12 weeks
Study: 17324145
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate 95 mg for 12 weeks, placebo for 2 weeks and then nebivolol 5 mg for 12 weeks
Study: 12066489
Drug: Southern Implants
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Southern Implants
Study: 12066489
Drug: All implant
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implant systems
Study: 1718158
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (encainide/flecainide)
Study: 6224684
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily
Study: 6224684
Drug: Cotrimoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole 160/800 mg twice daily
Study: 24832559
Drug: Film-coated ethionamide
Normalized name: ethionamide
DrugBank: Ethionamide (DB00609)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film-coated ethionamide tablets (250 mg)
Study: 24832559
Drug: Sugar-coated ethionamide
Normalized name: tiopronin
DrugBank: Tiopronin (DB06823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sugar-coated ethionamide tablets (250 mg)
Study: 17894303
Drug: Weight-based ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weight-based ribavirin (RBV) 800-1400 mg/day
Study: 17894303
Drug: Flat-dose ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flat-dose ribavirin (RBV) 800 mg/day
Study: 17894303
Drug: Flat-dose RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flat-dose RBV in genotype 1 patients
Study: 17894303
Drug: Flat-dose RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flat-dose RBV in genotype 1 patients with high baseline viral load
Study: 17894303
Drug: Flat-dose RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Flat-dose RBV in genotype 2/3 patients
Study: 9227164
Drug: etidronate +
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etidronate + sodium fluoride (NaF) 25 mg twice daily
Study: 7958497
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ANG II infusion
Study: 7958497
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ANG II infusion
Study: 30977767
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum sodium levels (≥141 mmol/L)
Study: 29033294
Drug: Acetaminophen 4,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4,000 mg/day + Diclofenac 150 mg/day
Study: 27737649
Drug: Benzodiazepine tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzodiazepine tapering
Study: 18249478
Drug: IFN-alpha as
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha as an adjuvant of HBV vaccine
Study: 18249478
Drug: Control (HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (HBV vaccine without IFN-alpha)
Study: 16754246
Drug: Semantic word
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Semantic word lists (e.g., bed, rest, wake)
Study: 16754246
Drug: Phonological word
Normalized name: OTOLOGICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonological word lists (e.g., pole, bowl, hole)
Study: 6941637
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to a cold room (‐10 degrees C) and inhalation of very cold air (‐35 degrees C)
Study: 6941637
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to 10 and 0 degrees C environmental temperature and inhalation of moderately cold air (‐10 degrees C)
Study: 28032303
Drug: Hydrocortisone (HCT)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HCT) administration
Study: 26338885
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol supplements of 10 μg/d for 3 mo
Study: 26338885
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol supplements of 25 μg/d for 3 mo
Study: 26338885
Drug: Oral cholecalciferol
Normalized name: cholecalciferol Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cholecalciferol supplements of 50 μg/d for 3 mo
Study: 21169285
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PET and VDT
Study: 8953681
Drug: Amoxicillin 1
Normalized name: amoxicillin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 1 g b.i.d. for 6 days
Study: 1789034
Drug: Lyophilized acellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized acellular staphylococcal vaccine
Study: 23864540
Drug: Oral thiamine
Normalized name: thiamine Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral thiamine hydrochloride 100 mg for 5 days
Study: 18244953
Drug: TPI ASM8
Normalized name: TPI-ASM8
DrugBank: TPI-ASM8 (DB05572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPI ASM8 (1,500 microg, inhaled by nebulizer, once daily for 4 days)
Study: 15697326
Drug: Zolmitriptan 5mg
Normalized name: ZOLMITRIPTAN 5MG TAB PKG 3
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan 5mg nasal spray
Study: 10932687
Drug: 1.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg.kg‐1 propofol
Study: 10932687
Drug: 2.5 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg.kg‐1 propofol
Study: 10932687
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose propofol (1.5 mg.kg‐1)
Study: 10932687
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose propofol (2.5 mg.kg‐1)
Study: 1768565
Drug: Atenolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (1 x 100 mg day‐1) for 6 weeks
Study: 1768565
Drug: Captopril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (1 x 100 mg day‐1) for 6 weeks
Study: 6817776
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (DSCG) 20 mg q.d.s.
Study: 6817776
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg b.d.
Study: 31927027
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 52 mg IUS
Study: 23904883
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) + Metformin
Study: 23019938
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) alone
Study: 21338805
Drug: High-milk, early-weaned:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-milk, early-weaned: fed 12 L/d of milk and weaned at 47 d of age
Study: 21338805
Drug: Low-milk, early-weaned:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-milk, early-weaned: fed 6 L/d of milk and weaned at 47 d of age
Study: 21338805
Drug: High-milk, later-weaned:
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-milk, later-weaned: fed 12 L/d of milk and weaned at 89 d of age
Study: 17418321
Drug: Hygiene promotion
Normalized name: PROMOTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hygiene promotion (medicine provided and hygiene promotion activity)
Study: 17418321
Drug: Treatment (medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (medicine provided, no hygiene promotion activity)
Study: 17418321
Drug: Seasonality (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonality (no medicine, no hygiene promotion activity)
Study: 16802774
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg daily
Study: 8500867
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg indomethacin for 5 days
Study: 30789808
Drug: Resveratrol 600
Normalized name: RESVERATROL 600 mg / NICOTINAMIDE MONONUCLEOTIDE 500 mg / WHITE PEPPER 50 mg ORAL CAPSULE [Ascuoli]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 600 mg daily for 12 weeks
Study: 27091274
Drug: Heel suspension
Normalized name: benzyl alcohol / lidocaine hydrochloride Topical Spray [Biochemistry Heel No Pain]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heel suspension device boot
Study: 24689967
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (4 g daily for 6 weeks)
Study: 24689967
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking capsules for 6 weeks)
Study: 20156150
Drug: Galantamine (8-32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8-32 mg for IR tablets; 8-24 mg for ER capsules)
Study: 20156150
Drug: Galantamine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine co-administered with ketoconazole
Study: 20156150
Drug: Galantamine co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine co-administered with paroxetine
Study: 18294323
Drug: Ifosfamide 9
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 9 g m(‐2) given by a 3 h infusion
Study: 18294323
Drug: Ifosfamide 9
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide 9 g m(‐2) given by a 72 h infusion
Study: 14516798
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (Group 3)
Study: 14516798
Drug: Topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical artificial tear substitute (ATS) (Group 1)
Study: 11368654
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of OSA-substituted starch
Study: 16139331
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/day plus Warfarin (INR 2.0‐2.5)
Study: 16139331
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Aspirin, Warfarin, or both)
Study: 3207127
Drug: Oral phenobarbital
Normalized name: phenobarbital Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phenobarbital (90 mg daily)
Study: 1920342
Drug: Labetalol (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (100-800 mg twice daily)
Study: 977134
Drug: Griseofulvin tablets
Normalized name: Griseofulvin Tablets
DrugBank: Griseofulvin (DB00400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Griseofulvin tablets containing dioctyl sodium sulfosuccinate, cetyl pyridinium chloride and polysorbate 80